Smad7 suppresses melanoma lung metastasis by impairing Tregs migration to the tumor microenvironment

Deliang Ma1, Li Qiao1, Bingnan Guo2,3

  • 1Department of Oncology, Linyi Central Hospital Linyi 276400, Shandong, China.

Insights

Smad7, an inhibitor of transforming growth factor β (TGF-β) signaling, suppresses melanoma lung metastasis by impairing regulatory T cells (Tregs) migration. This study highlights SMAD7

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Transforming growth factor β (TGF-β) signaling is crucial in physiological and pathological processes, including cancer.
  • SMAD7, an inhibitory SMAD, blocks TGF-β signaling and has shown tumor-suppressive roles in various cancers.
  • The specific role of SMAD7 in melanoma lung metastasis remains understudied.

Purpose of the Study:

  • To investigate the role of SMAD7 in melanoma cell viability and lung metastasis.
  • To explore the underlying mechanisms by which SMAD7 influences the tumor microenvironment.

Main Methods:

  • Overexpression of SMAD7 in the murine melanoma cell line B16-F10.
  • Assessment of cell viability, apoptosis, and cell cycle progression.
  • In vivo studies to evaluate lung metastasis.
  • Analysis of T cell activation and regulatory T cells (Tregs) infiltration in the tumor microenvironment.

Main Results:

  • SMAD7 overexpression slightly reduced B16-F10 cell growth, increased apoptosis, and caused S-phase cell cycle arrest.
  • In vivo experiments demonstrated that SMAD7 overexpression inhibited lung metastasis of B16-F10 cells.
  • SMAD7 promoted T cell activation by reducing the infiltration of Tregs into the tumor microenvironment.

Conclusions:

  • Tumor cell-derived SMAD7 acts as a suppressor of melanoma lung metastasis.
  • SMAD7 inhibits metastasis by impairing the migratory capacity of regulatory T cells (Tregs).
  • Targeting SMAD7 could be a potential therapeutic strategy for melanoma lung metastasis.